Literature DB >> 15916840

Reactions to small pox vaccine in naïve and previously-vaccinated individuals.

Cressida Auckland1, Alexandra Cowlishaw, Dilys Morgan, Elizabeth Miller.   

Abstract

Two hundred health care workers in England and Wales were vaccinated with the Lister/Elstree strain of the vaccinia virus, and completed health diaries for 21 days or until the lesion had scabbed over. Pain and temperature were measured daily, and all other symptoms recorded freehand by the vaccinee. One hundred and forty two (71%) vaccinees reported pain, of which 25% considered it to be moderate or severe; 32 vaccinees (16%) recorded a temperature of >37.7 degrees C, two of which exceeded 39 degrees C. Other, mainly trivial, adverse events were common; itch was reported in 72%, erythema in 27%, axillary pain or lymphadenopathy in 38%, malaise or flu-like symptoms in 40% and headache in 23%. The incidences of minor adverse events were lower in re-vaccinees, compared with naïve vaccine recipients, significantly so in the case of erythema and general malaise (p=0.001 and 0.006, respectively), perhaps reflecting pre-existing immunity. Major adverse events occurred in two vaccinees (hospital admission, one with cellulitis and one with headache and possible encephalitis), and a further five were treated with antibiotics for local cellulitis. This is the first study to report results derived from active follow-up by diaries in recipients of the Lister/Elstree strain of vaccinia, and to document reductions in trivial adverse events in re-vaccinees.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15916840     DOI: 10.1016/j.vaccine.2004.10.052

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge.

Authors:  Osmarie Martínez; Ariana Bravo Cruz; Saritza Santos; Maite Ramírez; Eric Miranda; Joanna Shisler; Miguel Otero
Journal:  Vaccine       Date:  2017-06-16       Impact factor: 3.641

Review 2.  Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications.

Authors:  Hajime Sato
Journal:  Environ Health Prev Med       Date:  2010-12-21       Impact factor: 3.674

3.  Poor Antigen Processing of Poxvirus Particles Limits CD4+ T Cell Recognition and Impacts Immunogenicity of the Inactivated Vaccine.

Authors:  Katherine S Forsyth; Brian DeHaven; Mark Mendonca; Sinu Paul; Alessandro Sette; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2019-01-30       Impact factor: 5.422

4.  Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?

Authors:  Holger F Rabenau; Ingrid Rapp; Jochen Steinmann
Journal:  BMC Infect Dis       Date:  2010-06-23       Impact factor: 3.090

5.  Long-term T cell memory to human leucocyte antigen-A2 supertype epitopes in humans vaccinated against smallpox.

Authors:  N D Ostrout; M M McHugh; D J Tisch; A M Moormann; V Brusic; J W Kazura
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

6.  Immunomodulator-based enhancement of anti smallpox immune responses.

Authors:  Osmarie Martínez; Eric Miranda; Maite Ramírez; Saritza Santos; Carlos Rivera; Luis Vázquez; Tomás Sánchez; Raymond L Tremblay; Eddy Ríos-Olivares; Miguel Otero
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

7.  Early Pro-Inflammatory Signal and T-Cell Activation Associate With Vaccine-Induced Anti-Vaccinia Protective Neutralizing Antibodies.

Authors:  Jue Hou; Shuhui Wang; Dan Li; Lindsay N Carpp; Tong Zhang; Ying Liu; Manxue Jia; Hong Peng; Chang Liu; Hao Wu; Yunda Huang; Yiming Shao
Journal:  Front Immunol       Date:  2021-10-11       Impact factor: 8.786

8.  Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.

Authors:  Claire M Midgley; Mike M Putz; Jonathan N Weber; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2008-12       Impact factor: 3.891

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.